Variable |
Overall N=55* |
PD N=25 |
WD N=9 |
ET+PD N=5 |
PSP N=8 |
Choreiform disorders n=5 |
Gender Males Females |
36 19 |
16 09 |
03 06 |
05 00 |
07 01 |
02 03 |
Mean age (years) |
55.6±18.1 |
64.16±10.6 |
24.8±5.4 |
52.6±2.8 |
69.12±8.6 |
55.2±13.4 |
Mean age at onset (Years) |
52.8±17.9 |
61.28±10.4 |
22.6±5.1 |
48.4±3.8 |
66.12±8.7 |
53.4±14.8 |
Mean duration (Years) |
2.8±1.07 |
2.9±1.0 |
2.2±0.8 |
4.2±1.0 |
3.0±0.8 |
1.8±1.0 |
Mean MMSE Scores |
24.8±2.2 |
23.5±
4.0 |
26.2±
3.2 |
26.3±4.3 |
19.2±2.2 |
25.7±
4.4 |
Variable |
Overall N=55*(%) |
PD N=25(%) |
WD N=9 |
ET+PD N=5 |
PSP N=8 |
Choreiform disorder N=5 |
Family
history |
08(14.5) |
4
(16) |
0 |
2
(40) |
0 |
2
(40%) |
Tremor Resting Postural Kinetic Intentional Re-emergent Head
Voice Chin
tremor |
26(47.2) 14(25.4) 09(16.3) 07(12.7) 06 05 05 08 |
17(68) 04(16) 00 00 06 00 00 08 |
4(44.4) 5(55.5) 4(44.4) 3(33.3) 0 5 5 0 |
3(60) 5(100) 5(100) 4(80) 0 5(100) 5(100) 0 |
2(25) 0 0 0 0 0 0 0 |
0 0 0 0 0 0 0 0 |
Dystonia
Hands Legs Trunk |
29(52.7%) 13(23.6%) 11(20%) |
11(44%) 4(16%) 5(20%) |
7(77.7) 3(33.3) 1(11.1) |
3(60%) 0 0 |
6(75%) 4(50%) 3(37.5%) |
2(40%) 2(40%) 2(40%) |
Falls
in history or examination |
24(43.6%) |
10(40%) |
3(33.3) |
2(40%) |
8(100%) |
1(20%) |
Pyramidal
signs |
5(09%) |
0 |
0 |
0 |
5(62.5%) |
0 |
Executive
dysfunction |
17(30.9%) |
9(36%) |
0 |
0 |
8(100%) |
0 |
Diabetes |
3(5.4%) |
0 |
0 |
0 |
0 |
3(60%) |
Hypertension |
2(3.6%) |
0 |
0 |
0 |
0 |
2(40%) |
Variable |
PD N=25 |
WD N=9 |
ET+PD N=5 |
PSP N=8 |
Choreiform disorder N=5 |
MMSE |
23.5±
4.0 |
26.2±
3.2 |
26.3±4.3 |
19.2±2.2 |
25.7±
4.4 |
FAB |
15.6±4.2 |
16.3±2.2 |
14.3±3.3 |
9.2±3.2 |
15.5±2.6 |
Mean MDS-UPDRS Part III OFF score |
57.7±13.2 |
NA |
46.2±10.8 |
NA |
NA |
Mean MDS-UPDRS Part III ON score |
28.2±10.2 |
NA |
37.6±8.3 |
NA |
NA |
Mean H and Y Stage OFF score |
2.2±0.7 |
NA |
2.7±1.2 |
NA |
NA |
Mean H and Y stage ON score |
1.7±0.6 |
NA |
2.0±0.8 |
NA |
NA |
Tremor Severity scales (TETRAS) |
NA |
NA |
22.8 |
NA |
NA |
GAS
for WD |
NA |
12.66±8.0 |
NA |
NA |
NA |
PSP-RS |
NA |
NA |
NA |
38.8±7.9 |
NA |
Mean
UCRS |
NA |
NA |
NA |
NA |
13.4±6.2 |
Response
to Drug therapy(mg/day) |
PD N=25(%) |
WD N=9(%) |
ET+PD N=5(%) |
PSP N=8(%) |
Chorieform N=5(%) |
Levodopa+Carbidopa-
375-400 |
G-
19(76) B-
6(24) |
B-4(44.4) |
B-5(100) |
B-3(37.5) P-5(62.5) |
NA |
Rasageline-1.5-2 |
G-
19(76) B-6(24) |
B-
4(44.4) |
B-
5(100) |
B-3(37.5) |
NA |
Ropinirole-1.5-2 |
G-19(76) B-6(24) |
B-4(44.4) |
B-
5(100) |
B-3(37.5) |
NA |
Pramipexole-1.5-2 |
G-19(76) B-6(24) |
NA |
B-5(100) |
B-3(37.5) |
NA |
Primidone-100-150 |
NA |
G-4(44.4) |
B-5(100) |
NA |
NA |
Zinc
sulphate-600 |
NA |
G-9(100) |
NA |
NA |
NA |
D-
Penicillamine-250 |
NA |
B-5(55.5) |
NA |
NA |
NA |
Trihexyphenidyl-6-12 |
G-18(72) B-7(28) |
G-9(100) |
B-5(100) |
B-3(37.5) |
NA |
Propanolol-40-80 |
B-6(64) |
G-9(100) |
G-5(100) |
NA |
NA |
Clonazepam-0.5-1.0 |
NA |
B-9(100) |
G-5(100) |
NA |
B-5(100) |